NCT00419445

Safety and Efficacy of GTS21 in Adults With Attention-deficit Hyperactivity Disorder

A Double-Blind, Randomized, Proof-of-Concept Crossover Trial to Assess the Effects of GTS21 on Cognitive Function, Clinical Symptoms, and Adverse Events in Adults Diagnosed With Attention-Deficit Hyperactivity Disorder

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 37 (actual)
• Sponsor: CoMentis · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Not accepted

Summary

This study will be a randomized, double-blind, placebo-controlled crossover study to assess the effects of GTS21 (25 mg three times a day (tid), 75 mg tid, 150 mg tid) compared to placebo in non-smoking adults aged 18-55 with a diagnosis of ADHD, any subtype.

Conditions

• Attention Deficit Hyperactivity Disorder

Interventions

Type	Name	Description
DRUG	GTS21/Placebo

Timeline

• Start date: 2007-02-01
• Primary completion: 2008-01-01
• Completion: 2008-01-01
• First posted: 2007-01-08
• Last updated: 2010-09-10
• Results posted: 2010-09-10

Locations

2 sites across 1 country: United States